Search
Enlivex Therapeutics Ltd
ENLVAdd to Watchlist
0.528USD
-0.014-2.58%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
125.24MMarket Cap
0.02P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.58%
5 Days
-9.11%
1 Month
-37.92%
6 Months
-30.11%
Year to Date
-24.97%
1 Year
-53.31%
Key Figures
0.540Open
0.575High
569.44KVolume
0.02P/E TTM
LossP/E Dynamic
--Dividend TTM
0.24%Turnover Ratio
0.542Prev. Close
0.520Low
200.22KTurnover
LossP/E Static
0.06P/B
0.00%Div Yield TTM
104.94%ROA
2.10052wk High
2.63Volume Ratio
-15.01MNet Profit
237.38MShares
27.0379EPS TTM
1.67Beta
126.17%ROE
0.66052wk Low
10.14%Amplitude
--Gross Margin
125.24MMarket Cap
-7.06Reward/Risk
5.14%Risk Rate
TradingKey Stock Score of Enlivex Therapeutics Ltd
Currency: USD Updated: 2026-07-02Key Insights
Enlivex Therapeutics Ltd's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 176 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enlivex Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Enlivex Therapeutics Ltd Highlights
StrengthsRisks
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 0.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.13M shares, decreasing 41.59% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 747.23K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
20.000
Target Price
+3348.28%
Upside Space
Enlivex Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Enlivex Therapeutics Ltd Info
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Ticker SymbolENLV
CompanyEnlivex Therapeutics Ltd
CEOHershkovitz (Oren)
Websitehttps://www.enlivex.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53029.700
+187.200 (+0.35%)
29550.200
+238.800 (+0.81%)
7505.200
+33.700 (+0.45%)
15059.000
+256.000 (+1.73%)
69456.000
+1308.000 (+1.92%)
6380.400
+27.600 (+0.43%)
68.950
+0.606 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.650
+55.740 (+1.35%)
FAQs
What is the current price of Enlivex Therapeutics Ltd (ENLV)?
The current price of Enlivex Therapeutics Ltd (ENLV) is 0.53.
What is the symbol of Enlivex Therapeutics Ltd?
The ticker symbol of Enlivex Therapeutics Ltd is ENLV.
What is the 52-week high of Enlivex Therapeutics Ltd?
The 52-week high of Enlivex Therapeutics Ltd is 2.10.
What is the 52-week low of Enlivex Therapeutics Ltd?
The 52-week low of Enlivex Therapeutics Ltd is 0.66.
What is the market capitalization of Enlivex Therapeutics Ltd?
The market capitalization of Enlivex Therapeutics Ltd is 125.24M.
Is Enlivex Therapeutics Ltd (ENLV) currently rated as Buy, Hold, or Sell?
According to analysts, Enlivex Therapeutics Ltd (ENLV) has an overall rating of Buy, with a price target of 20.00.
What is the Earnings Per Share (EPS TTM) of Enlivex Therapeutics Ltd (ENLV)?
The Earnings Per Share (EPS TTM) of Enlivex Therapeutics Ltd (ENLV) is 27.04.